Company Overview and News

 
Dollar falls amid speculation over US tax cuts

2018-05-23 nzherald.co.nz
The New Zealand dollar fell against the US dollar ahead of minutes from the last US Federal Reserve policy meeting and after US President Donald Trump hinted at further tax cuts.

 
Confidence slipping in small business community

2018-05-23 nzherald.co.nz
New Zealand small businesses are less optimistic about the future as successive years of robust economic growth appear to have peaked, although the big end of town still has grand aspirations, according to a Westpac Banking Corp survey.

 
Why Hong Kong homebuyers should take note if city’s aggregate balance dips below HK$100 billion

2018-05-22 scmp
With several indicators suggesting Hong Kong dollar liquidity is becoming tighter, banks’ higher borrowing costs could translate into higher mortgage repayments for homeowners

 
Evicting a blind old woman is Westpac's public relations debacle

2018-05-21 theage.com.au
Big business borrowers have size on their side, consumers have a significant measure of protection through laws - but small business borrowers are deficient on both counts when it comes to dealing with banks.

 
Evicting a blind old woman is Westpac's public relations debacle

2018-05-21 smh.com.au
Big business borrowers have size on their side, consumers have a significant measure of protection through laws - but small business borrowers are deficient on both counts when it comes to dealing with banks.

 
New Zealand dollar falls against US

2018-05-21 nzherald.co.nz
The New Zealand dollar fell against the greenback after first quarter retail spending was softer-than-expected, pointing to sluggish economic growth.

 
WBK / Westpac Banking Corp. Ltd. 6-K (Current Report of Foreign Issuer)

2018-05-18 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549

 
Australia's Westpac hires complaints head amid damaging inquiry

2018-05-18 reuters
SYDNEY (Reuters) - No. 2 Australian lender Westpac Banking Corp (WBC.AX) said on Friday it had been “too slow” to resolve customer complaints and had created an executive role to handle them, as the country’s financial sector responds to revelations of serious misconduct.

 
Australia's Westpac hires complaints head amid damaging inquiry

2018-05-18 channelnewsasia
SYDNEY: No. 2 Australian lender Westpac Banking Corp said on Friday it had been "too slow" to resolve customer complaints and had created an executive role to handle them, as the country's financial sector responds to revelations of serious misconduct.

 
Shares rise, led by A2 and Synlait

2018-05-17 nzherald.co.nz
New Zealand shares rose, led by A2 Milk Co and Synlait Milk while Pushpay fell after annual earnings met its guidance, disappointing some upbeat investors.

 
Dollar holds above 69 US cents as budget shows fiscal discipline

2018-05-17 nzherald.co.nz
The New Zealand dollar held above 69 US cents after Finance Minister Grant Robertson continued to project fiscal surpluses and a gradual reduction in debt in the government's first budget.

 
What to Expect in New Zealand's Budget Beyond Another Surplus - Bloomberg

2018-05-15 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

 
How Misbehaving Australian Banks Are Causing Global Pain - Bloomberg

2018-05-14 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

 
WBK / Westpac Banking Corp. Ltd. 424B5 (Prospectus)

2018-05-10 sec.gov
Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

16h - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

17h - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

CUSIP: 961214301